Correlation Between UroGen Pharma and Dominari Holdings

Can any of the company-specific risk be diversified away by investing in both UroGen Pharma and Dominari Holdings at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining UroGen Pharma and Dominari Holdings into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between UroGen Pharma and Dominari Holdings, you can compare the effects of market volatilities on UroGen Pharma and Dominari Holdings and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in UroGen Pharma with a short position of Dominari Holdings. Check out your portfolio center. Please also check ongoing floating volatility patterns of UroGen Pharma and Dominari Holdings.

Diversification Opportunities for UroGen Pharma and Dominari Holdings

0.3

Correlation Coefficient

UroGen Pharma  Dominari Holdings

Weak diversification

The 3 months correlation between UroGen and Dominari is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding UroGen Pharma and Dominari Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dominari Holdings and UroGen Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on UroGen Pharma are associated (or correlated) with Dominari Holdings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dominari Holdings has no effect on the direction of UroGen Pharma i.e., UroGen Pharma and Dominari Holdings go up and down completely randomly.

Pair Corralation between UroGen Pharma and Dominari Holdings

Given the investment horizon of 90 days UroGen Pharma is expected to under-perform the Dominari Holdings. But the stock apears to be less risky and, when comparing its historical volatility, UroGen Pharma is 1.34 times less risky than Dominari Holdings. The stock trades about -0.02 of its potential returns per unit of risk. The Dominari Holdings is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  161.00  in Dominari Holdings on September 2, 2024 and sell it today you would earn a total of  8.00  from holding Dominari Holdings or generate 4.97% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

UroGen Pharma  vs.  Dominari Holdings

UroGen Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days UroGen Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, UroGen Pharma is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

Dominari Holdings

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Dominari Holdings are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak primary indicators, Dominari Holdings may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with UroGen Pharma and Dominari Holdings

The main advantage of trading using opposite UroGen Pharma and Dominari Holdings positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if UroGen Pharma position performs unexpectedly, Dominari Holdings can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dominari Holdings will offset losses from the drop in Dominari Holdings' long position.

The idea behind UroGen Pharma and Dominari Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.